panflu Stats Forum Indexpanflu Stats
Influenza Pandemic Science, Statistics and News
 FAQFAQ   SearchSearch   MemberlistMemberlist   UsergroupsUsergroups   RegisterRegister 
 ProfileProfile   Log in to check your private messagesLog in to check your private messages   Log inLog in            Calendar

BioCryst's Peramivir Update

Post new topic   Reply to topic    panflu Stats Forum Index -> Vaccine Development
View previous topic :: View next topic  
Author Message

Joined: 15 Dec 2007
Posts: 1419


PostPosted: Thu Jul 23, 2009 1:51 pm    Post subject: BioCryst's Peramivir Update Reply with quote

Summary: Clinical trials that are finished have given positive results. FDA has proceeded with a pre-Emergency Use Authorization (EUA) review of peramivir, and if an order is placed for the Strategic National Stockpile, BioCryst has the manufacturing supplies it needs to finish the product and make large quantities available.


Peramivir is a potent, specific influenza viral neuraminidase inhibitor (NAI) discovered at BioCryst that will be used for uncomplicated influenza and influenza requiring hospitalization. Parenteral peramivir is now completing phase-3 clinical trials conducted by BioCryst's partner Shionogi & Co. Ltd. in Japan (enrollment is completed but data is not yet available) and is ready to enter phase-3 trials in the United States for influenza indications.

These expanded studies of 204 unique clinical isolates have demonstrated that this new virus is very sensitive to peramivir, with a median IC50 of 0.09nM in the NAI chemiluminesence assay; the IC50 for peramivir is significantly lower than that for either zanamivir or oseltamivir (p < 0.001). Peramivir improves survival in preclinical influenza models, including mouse and ferret models of highly pathogenic avian influenza H5N1. One day of peramivir treatment is active, and multiple days of treatment rescues most or all mice with H5N1. Similar results have been observed in ongoing murine experiments with seasonal influenza A (H1N1)/H274Y.

Peramivir achieves very high plasma levels after parenteral administration, is not metabolized, and is cleared by renal filtration. It has a long half-life, especially compared with other NAIs. Because the drug is not metabolized, is widely distributed, and is excreted unchanged in urine, dosing regimens can be adapted easily for patients with renal impairment and for pediatric populations.

Clinical data has been generated for peramivir in several phase-2 and phase-3 studies, and the drug has been administered safely to more than 1,300 subjects in clinical studies.

The primary endpoint (in the Japan studies) was time to alleviation of symptoms (TTAS) and was unequivocally positive. The time to alleviation of symptoms was 81.8 hours for placebo, and was shortened by about 22 hours with peramivir (p=0.0046). Time to resolution of fever was also significantly improved in the peramivir groups compared to placebo. Evaluations in the change in viral load showed that viral clearance was significantly accelerated in the 600mg peramivir group compared to placebo.

The safety experience for peramivir was very satisfactory in this study. Reported AEs were mild, and no serious AEs were reported in the 198 subjects administered peramivir in the study. The reported AEs were of similar frequency and severity grade in the placebo and treatment groups.

BioCryst's phase-2 study of peramivir in patients with influenza requiring hospitalization
An important issue for influenza clinical research is lack of awareness of influenza in the hospital setting. This problem seems partly due to lack of reliable diagnostic tests in emergency rooms - it is estimated that only 5% of patients hospitalized with influenza actually receive that diagnosis.

The patient population enrolled consisted mostly of individuals admitted with chronic illness that worsened with influenza, and not patients with influenza-pneumonia. The study patients had good clinical outcomes, and BioCryst was pleased with the rapidity of clearance of the virus. Viral cultures were obtained from nasopharyngeal swabs at regular intervals. Overall, viral load was reduced rapidly with treatment.

Looking at AEs, peramivir IV once daily for 5 days was generally safe and well-tolerated in adults hospitalized with acute influenza.

Dr. Sheridan described one case of compassionate use of peramivir under emergency IND regulations in Seattle. Data for the presentation was kindly provided by the investigator, Dr. Anna Wald, Seattle WA. This patient had had a bone marrow transplant and presented to the ED with respiratory and GI symptoms 2 days after the transplant. The patient was diagnosed with influenza A (subsequently confirmed to be due to the pandemic strain) developed bilateral viral pneumonia, and rapidly deteriorated despite treatment with oseltamivir, adamantane and ribavirin. Virus was detected by PCR in blood and stool as well as bronchoalveolar lavage specimens. Intubation, 100% inspired oxygen and positive end-expiratory pressure were required. Following a 10-day course of peramivir combined with oseltamivir, the patient's condition improved, allowing discharge from the intensive care unit and cessation of antivirals. Dr. Sheridan said that although the case provides anecdotal evidence, it illustrates the potential for successful use of peramivir for severe illness.

Peramivir can be made available as a countermeasure for the current H1N1 pandemic. FDA has proceeded with a pre-Emergency Use Authorization (EUA) review of peramivir, and if an order is placed for the Strategic National Stockpile, BioCryst has the manufacturing supplies it needs to finish the product and make large quantities available. The manufacturing process is well developed.

From the influenza workshop; 100 page .pdf
Back to top
View user's profile Send private message

Joined: 25 Apr 2009
Posts: 76
Location: Germany


PostPosted: Mon Sep 14, 2009 1:10 pm    Post subject: New Drug Fights Flu as Well as Tamiflu Does, Study Says Reply with quote

Researchers delivered a double dose of good news Sunday in the fight against flu: successful tests of what could become the first new flu medicine in a decade, and the strongest evidence yet that such drugs save lives, not just shorten illness.

A single intravenous dose of the experimental drug, peramivir, cleared up flu symptoms as well as five days of Tamiflu pills did, a large study in Asia found. An IV treatment is badly needed because many sick people can't swallow pills and because illness hinders the body's ability to absorb oral medicines.

Several other studies showed the value of treatment with Tamiflu. In one study of hundreds of people stricken with bird flu around the world, half of those given Tamiflu survived, while nearly 90 percent of those not given flu medicines died. Other research showed Tamiflu improved survival from regular seasonal flu, too.

"There has been an accumulation of evidence over time that the antiviral drugs can save lives," and the new studies confirm that hope, said Nancy Cox, flu chief at the U.S. Centers for Disease Control and Prevention.

Results were reported Sunday at an American Society for Microbiology conference in California. It is the first big meeting of infectious disease specialists since the new H1N1 swine flu emerged in April. Treatment options are getting huge attention because it will take a month or more for people to get swine flu vaccine and have time to develop immunity from the shot.

Peramivir (purr-AM-uh-veer) was tested in nearly 1,100 people with seasonal flu last winter in Asia. They were given either Tamiflu pills for five days or a single infusion of 300 or 600 milligrams of peramivir.

Symptoms cleared in about 78 hours and 81 hours with lower and higher doses of peramivir, respectively, and in 82 hours with Tamiflu. Adverse drug reactions were less common with peramivir, said study leader Dr. Shigeru Kohno of Nagasaki University in Japan.

The fact peramivir is not a pill like Tamiflu or an inhaled drug like Relenza makes it less convenient yet "very promising" and valuable medically, Cox said.

"You can get it into the blood, into the lungs, where infection is occurring," she explained.

Others were cautious.

"I'm very enthusiastic about peramivir for hospitalized patients," but it was compared in a season when many flu cases were at least somewhat resistant to Tamiflu, said Dr. Frederick Hayden, a virus expert at the University of Virginia and a World Health Organization flu consultant.

BioCryst Pharmaceuticals Inc., of Birmingham, Ala., is developing peramivir with Japan-based Shionogi & Co. The U.S. government gave a major grant for its development, and officials have been discussing stockpiling the drug as part of flu pandemic preparedness plans.

Please read the full article here:,2933,549842,00.html
Back to top
View user's profile Send private message
Display posts from previous:   
Post new topic   Reply to topic    panflu Stats Forum Index -> Vaccine Development All times are GMT
Page 1 of 1

Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum
panflu Stats topic RSS feed 

Powered by phpBB © 2001, 2005 phpBB Group
FREE FORUM HOSTING by AtFreeForum. Terms of Service - Privacy Policy